181-195 of 344
Emerging Directions in Menin-Directed AML Therapy
MinuteCE®Emerging Directions in Menin-Directed AML Therapy
Ghayas Issa, MD
Amir Fathi, MD
Ongoing Clinical Trials in AML With Menin Inhibitors
MinuteCE®Ongoing Clinical Trials in AML With Menin Inhibitors
Ghayas Issa, MD
Amir Fathi, MD
Ghayas Issa, MD
Amir Fathi, MD
Advancing Molecular Therapies to First Line in BRAF-Mutated mCRC: Insights From Emerging Data
MinuteCE®Advancing Molecular Therapies to First Line in BRAF-Mutated mCRC: Insights From Emerging Data
Scott Kopetz, MD, PhD
Cathy Eng, MD, FACP
Case Consult: Current Standards and Emerging Directions in BRAF-Mutant mCRC Care
MinuteCE®Case Consult: Current Standards and Emerging Directions in BRAF-Mutant mCRC Care
Scott Kopetz, MD, PhD
Cathy Eng, MD, FACP
Maximizing Outcomes: Strategic Approaches in Metastatic CRC Treatment
MinuteCE®Maximizing Outcomes: Strategic Approaches in Metastatic CRC Treatment
Scott Kopetz, MD, PhD
Cathy Eng, MD, FACP
- advertisement
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
CME/CEContrasting TROP2-Targeted ADCs in Breast Cancer Therapy
Kevin Kalinsky MD, MS
Komal Jhaveri, MD, FACP
Pulmonary Hypertension: Getting the Right Diagnosis and Knowing When to Refer
CME/CE Broadcast ReplayPulmonary Hypertension: Getting the Right Diagnosis and Knowing When to Refer
Vallerie V. McLaughlin, MD
Marsha Burks, BSN, RN
Rajan Saggar, MD
Expert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer
CME/CEExpert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer
Neal Shore, MD, FACS
Sarah Psutka, MD, MS
Enhancing Diagnosis, Treatment, and Outcomes in Paroxysmal Nocturnal Hemoglobinuria with Novel Oral Therapeutics
CME/CEEnhancing Diagnosis, Treatment, and Outcomes in Paroxysmal Nocturnal Hemoglobinuria with Novel Oral Therapeutics
Carlos M. de Castro, MD
Patient-Centric ADT Intensification in Hormone-Sensitive Prostate Cancer: Balancing Efficacy, Safety, Quality of Life, and Survival
CME/CE Broadcast ReplayPatient-Centric ADT Intensification in Hormone-Sensitive Prostate Cancer: Balancing Efficacy, Safety, Quality of Life, and Survival
Mary-Ellen Taplin, MD
Harry Yoon, MD
Jaffer Ajani, MD
- advertisement
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
MinuteCE®Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
Jaffer Ajani, MD
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
MinuteCE®The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
Harry Yoon, MD
Effective Monitoring and Management of Adverse Effects in Metastatic ESCC
MinuteCE®Effective Monitoring and Management of Adverse Effects in Metastatic ESCC
Harry Yoon, MD
Jaffer Ajani, MD
